GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NeuroOne Medical Technologies Corp (NAS:NMTC) » Definitions » Cash Conversion Cycle

NeuroOne Medical Technologies (NeuroOne Medical Technologies) Cash Conversion Cycle : 100.21 (As of Mar. 2024)


View and export this data going back to 2012. Start your Free Trial

What is NeuroOne Medical Technologies Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

NeuroOne Medical Technologies's Days Sales Outstanding for the three months ended in Mar. 2024 was 36.41.
NeuroOne Medical Technologies's Days Inventory for the three months ended in Mar. 2024 was 135.03.
NeuroOne Medical Technologies's Days Payable for the three months ended in Mar. 2024 was 71.23.
Therefore, NeuroOne Medical Technologies's Cash Conversion Cycle (CCC) for the three months ended in Mar. 2024 was 100.21.


NeuroOne Medical Technologies Cash Conversion Cycle Historical Data

The historical data trend for NeuroOne Medical Technologies's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuroOne Medical Technologies Cash Conversion Cycle Chart

NeuroOne Medical Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -626.28 -406.75 106.15

NeuroOne Medical Technologies Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 57.89 123.07 133.21 171.83 100.21

Competitive Comparison of NeuroOne Medical Technologies's Cash Conversion Cycle

For the Medical Devices subindustry, NeuroOne Medical Technologies's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeuroOne Medical Technologies's Cash Conversion Cycle Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NeuroOne Medical Technologies's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where NeuroOne Medical Technologies's Cash Conversion Cycle falls into.



NeuroOne Medical Technologies Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

NeuroOne Medical Technologies's Cash Conversion Cycle for the fiscal year that ended in Sep. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=6.17+296.88-196.9
=106.15

NeuroOne Medical Technologies's Cash Conversion Cycle for the quarter that ended in Mar. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=36.41+135.03-71.23
=100.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NeuroOne Medical Technologies  (NAS:NMTC) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


NeuroOne Medical Technologies Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of NeuroOne Medical Technologies's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


NeuroOne Medical Technologies (NeuroOne Medical Technologies) Business Description

Traded in Other Exchanges
N/A
Address
7599 Anagram Dr., Eden Prairie, MN, USA, 55344
NeuroOne Medical Technologies Corp operates as a medical technology company. It is focused on the development and commercialization of thin-film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, brain stimulation, and ablation solutions for patients suffering from brain-related disorders. The company business is in one operating segment, which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording, monitoring, ablation, and brain stimulation solutions.
Executives
Mark Christianson 10 percent owner, officer: VP, Business Dev and Marketing 10006 LIATRIS LANE, EDEN PRAIRIE MN 55347
Ronald W. Mcclurg officer: Chief Financial Officer C/O NEUROONE MEDICAL TECHNOLOGIES CORP, 7599 ANAGRAM DR, EDEN PRAIRIE MN 55344
David A Rosa director, officer: CEO and President 10901 RED CIRCLE DRIVE, SUITE 150, MINNETONKA MN 55343
Hijaz Haris officer: VP of Marketing C/O NEUROONE MEDICAL TECHNOLOGIES CORP, 7599 ANAGRAM DR, EDEN PRAIRIE MN 55344
Morgan C. Frank 10 percent owner 2 CALLE NAIRN, UNIT 701, SAN JUAN PR 00907
Manchester Management Co Llc 10 percent owner 3 WEST HILL PLACE, BOSTON MA 02110
Manchester Explorer, L.p. 10 percent owner MANCHESTER MANAGEMENT COMPANY, L.L.C, 3 WEST HILL PLACE, Boston ma 02114
James E Besser 10 percent owner 3 WEST HILL PLACE, BOSTON MA 02114
Manchester Management Pr, Llc 10 percent owner 3 WEST HILL PLACE, BOSTON MA 02114
Edward Andrle director C/O NEUROONE MEDICAL TECHNOLOGIES CORP, 7599 ANAGRAM DRIVE, EDEN PRAIRIE MN 55344
Wade Fredrickson 10 percent owner 10006 LIATRIS LANE, EDEN PRAIRIE MN 55347
Steve Mertens officer: Chief Technology Officer 10901 RED CIRCLE DR., SUITE 150, MINNETONKA MN 55343
Scott Heuler officer: Vice President of Sales 10901 RED CIRCLE DR., SUITE 150, MINNETONKA MN 55343
Paul Buckman director 12988 VALLEY VIEW RD, EDEN PRAIRIE MN 55402
Suraj Kalia director 10006 LIATRIS LANE, EDEN PRAIRIE MN 55347